before several years, the UK has witnessed a revolution in clinical weight‑loss treatment options — within the introduction of semaglutide (Wegovy®) into the escalating popularity of tirzepatide (Mounjaro®). Now, One more title is drawing focus in the two clinical and public wellbeing circles: Re